




Market Outlook: Asian indices are marginally down today while we may not react too much to the advanced GDP estimates which came on Friday evening. After the opening, the Nifty may consolidate between the Critical support at 8228 and the first resistance at 8266. If stays above this after the initial move, then it could face resistance at 8290. During the day a fall below 8228 could find lower support at 8212. The major support is at 8182.



Global: U S markets ended near their lifetime highs on Friday, as sentiment got a boost from strong non-farm employment data for December. Non-farm payrolls rose less than expected, but a rebound in wages highlighted sustained labour market momentum that points to stronger growth. Gains were led by technology stocks. Nasdaq closed up 0.60% driven by 1.5-2.0% rise in shares of Apple Alphabet, Facebook, Amazon and Netflix. Key Asian indices are trading mixed with no major gains or losses. Nikkei is shut today on account of Coming-of-Age Day.

Country	LTP	Change	% Change
US DOW	19964	65	0.32
Nasdaq	5007	42	0.85
Germany-DAX	11599	14	0.12
France	4910	9	0.19
UK - FTSE	7210	15	0.2
HongKong	22516	13	0.06
JAPAN	19454	0	0
CHINA	3158	3	0.1
THAILAND	2221	-2	-0.11

Data to Watch: FII Cash -255cr, DII Cash +165cr

Brent Crude: 56.95/bbl; Rupee: 67.96/\$1; Gold: \$1,173.4/ounce; 10-yr yld: 6.3850%

Union Budget 2017 to be presented on February 1

GDP: Growth is estimated to slow down to 7.1% in current fiscal, from 7.6% in 2015-16, mainly due to slump in manufacturing, mining and construction sectors according to CSO advance estimates. The impact of demonetisation has not been considered in the forecast.

Jan 11: U S President-elect Trump will take questions from the press for the first time since the election.

Stocks in News:

Positive: AUROBINDO PHARMA: On January 7 informed exchanges that its wholly owned step-down subsidiary, Agile Pharma BV, Netherland has entered into an agreement to acquire 100% shareholdings in Generis Farmaceutica SA, a Portuguese pharmaceutical company engaged in the manufacture and marketing of pharma products in Portugal for a consideration of Euro 135 mln or Rs.970 crores. Has also received the US Food and Drug Administration's approval for generic Levetiracetam injectable, in 15 mg per ml strength.

Neutral: BAJAJ AUTO: Has said demands of company's workers' union, threatening to go on a two-day hunger strike on Saturday, at its Chakan and Akurdi plants were unreasonable and unrealistic. BEML: Informed exchanges that the Ministry of Defence has communicated 'in-principal' approval of the Cabinet Committee on Economic Affairs (CCEA), for strategic disinvestment of 26% equity shares out of Government of India shareholding of 54.03%. BOMBAY DYEING: Has roped in PricewaterhouseCoopers, Microsoft, KPMG and Ernst and Young to restructure its retail business and turn it profitable as early as the next fiscal year. DHFL: Board will, on Jan 16, consider raising up to 60 bln rupees through the issuance of non-convertible debentures. HT MEIDA: English language daily Hindustan Times has decided to wind up print editions in four cities as part of its plan to focus on expanding digital presence. NALCO: After a record 18% growth in bauxite mining, the company plans to raise its production capacity to over 7.3 mln tn this fiscal from about 6.8 mln tn. ONGC: Is close to finalising ways to complete its projects worth \$800 mln that are stuck midway after the contactor, Singapore's Swiber Holdings, collapsed after an oil slump last year. TATA MOTORS: Arm Jaguar Land Rover plans to buy a minority stake in connected car technology firm CloudCar, as automakers seek out new partnerships and investments to build high-tech models.

Negative: GRANULES INDIA: Informed exchanges that INFARMED Portugal, had conducted a renewal inspection of the company's facility located at Gagillapur, Telangana. In this respect, the company on January 6, has received the inspection report from INFARMED with 11 observations. The Gagillapur facility manufactures Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). SOBHA: he company's sales fell 22.9% on year to 3.73 bln rupees in Oct-Dec, hit by the government's demonetisation move. The company during the third quarter ended December 31, 2016 has achieved new sales volume of 613652 square feet valued at Rs 3732 million with an average realisation of Rs 6082 per square feet.

Fund Action: FORTIS HEALTHCARE: Standard Chartered Pvt Equity (Mauritius) III A sold 4.37 mln shares, or 0.91% stake in the company at 191.37 rupees per share. GEOMETRIC: Reliance Mutual Fund, via Reliance Arbitrage Advantage Fund, bought 355,180 shares, or 0.54% stake in the company at 250.91 rupees a share.

indi15

Stock	QTY	Rate	Value	CMP	Current Value
Amara Raja Bat	100	861	86100	930.4	93040
COLGATE	100	872.6	87260	899.15	89915
LIC HOUSING	100	508.25	50825	524.6	52,460
Triveni Turbine	400	128.57	51428	118.45	47,380
Asian Paints	100	849.80	84980	929.5	92,950
HCL TECH	100	816.00	81600	814.40	81,440
ITC	450	216.00	97200	242.7	109,215
Kotak Bank	100	660.75	66075	716.85	71,685
Marico	300	242.20	72660	260.4	78,120
Praj Ind	700	87.35	61145	83.90	58,730
Reliance Ind	100	1,031.40	103140	1074.95	107,495
Sarla Perfo Fibers	700	64.46	45122	64.35	45,045
SYNGENE	200	382.60	76520	582.55	116,510
ZEE Ent	200	415.88	83176	463.1	92,620
SBIN	200	279.70	55940	245.9	49,180
			1,103,171		1,185,785
Profit/Loss Booked	QTY	Entry	Value	Exited@	
Aditya Birla Nuvo	100	829	82900	1002	100,200
ZEEL	100	388.85	38885	439	43,900
Repcos Home	100	590.05	59,005	670.2	67,020
Motherson Sumi	300	253.8	76,140	282.1	84,630
TataMotors	300	377.7	113,310	424.25	127,275
PI IND	100	579.7	57,970	687	68,700

Notional P/L	83,607
Profit Booked	63,515
Total Profit	147,122
Current NAV	1,302,595
% Gain	12.73
Initial Value	1,155,473
Nifty on Mar 23	7716.5
NIFTY.NSI	8259.35
% Change	7.03

indiCAP 15

Emerging Stories

Name	QTY	Entry Rate	Entry Value	CMP	VALUE
APAR INDUSTRIES LTD	200	471.59	94318	613.1	122,620.00
ASTRAL POLY TECHNIK LTD	100	437.87	43787	390.85	39,085.00
AVANTI FEEDS LTD	100	448.45	44845	528.85	52,885.00
CAPITAL FIRST LTD	200	503.33	100666	602.1	120,420.00
GARWARE WALL ROPES LTD	100	343.68	34368	629.35	62,935.00
GODREJ PROPERTIES LTD	200	321.28	64256	316.15	63,230.00
GREENPLY INDUSTRIES LTD	300	216.03	64809	248.35	74,505.00
LA OPALA RG LTD	100	576.97	57697	468.5	46,850.00
MOLD-TEK PACKAGING LTD	200	181.65	36330	200	40,000.00
SADBHAV ENGINEERING LTD	200	274.52	54904	273.35	54,670.00
SAGAR CEMENTS LTD	200	574.26	114852	687.6	137,520.00
SHILPA MEDICARE	200	477.25	95450	698.1	139,620.00
SUPRAJIT ENGINEERING LTD	200	171.06	34212	194.5	38,900.00
SRIPIPES	100	278.85	27885	277.4	27,740.00
AIA ENGG	100	1315	131500	1270	127,000.00
			999879		1,147,980.00
STOCKS EXITED					
GARWARE WALL ROPES LTD	100	343.68	34368	358.04	35,804.00
SUPRAJIT	200	148.62	29724	172.1	34,420.00
ASTRAL POLY	100	437.85	43785	452	45,200.00
Avanti Feeds	100	448.45	44845	478	47,800.00
Mold-tek Packaging	200	156.95	31390	163	32,600.00
KPR MILLS	100	879.7	87970	980.4	98,040.00
HERITAGE FOODS LTD	100	514.56	51456	932	93,200.00

Entry Rate	1124045
Gain for 100 unit	211,627
% Gain of 100 unit	18.83
Nifty 500 on May 11	6593
Nifty 500 Today	7083.1
% Gain in Nifty500	7.43

Prepared by: Inditrade Capital Limited NSE - INZ230012437 BSE - INZ010012433 MSEI - INZ260012430
NSDL DP ID:IN301895 CDSL DP ID:12048100 NMCE:CL0101 NCDEX:00224| MCX:10190 IPSTA:351 MUTUAL FUNDS:ARN
53315

Customer Care :18605006543 / 0484-4100200

Send your grievances to investorgrievance@inditrade.com | Customer Care Email-id customercare@inditrade.com

Analyst Certification: The analyst for this report certifies that all of the views expressed in this report accurately reflect his personal views about the subject company or companies and its or their securities, and no part of his compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Neither the analyst, nor Inditrade Capital holds not more than 1% in any of the company discussed in this report. The analyst is neither a previous employee nor, getting any kind of remuneration from any of the company discussed in this report. **SEBI Reg No: INH200001418**

Disclaimer :This report has been prepared by Inditrade Capital Ltd. This does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Inditrade capital reserves the right to make modifications and alterations to this statement as may be required from time to time. Inditrade or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Inditrade Capital nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views in the report.